

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)



(10) International Publication Number
WO 2022/005979 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C12N 15/09 (2006.01)
C07K 16/46 (2006.01) C12N 15/13 (2006.01)
C07K 19/00 (2006.01)

(21) International Application Number:

PCT/US2021/039389

(22) International Filing Date:

28 June 2021 (28.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/045,687 29 June 2020 (29.06.2020) US

(71) Applicant: ALLINAIRE THERAPEUTICS, LLC

[US/US]; c/o BioMotiv, 20600 Chagrin Boulevard, Suite 210, Cleveland, Ohio 44122 (US).

(72) Inventors: HAY, Douglas W.P.; 278 Colket Lane, Stra-

ford, Pennsylvania 19087 (US). BEREZOVSKY, Suzanne E.; 2868 Washington Boulevard, Cleveland Heights, Ohio 44118 (US). KNIGHT, David; 5733 North Via Amable, Tucson, Arizona 85750-1213 (US). HUANG, Kexin; c/o LakePharma, Inc., 530 Harbor Boulevard, Belmont, Cal-

ifornia 94002 (US). WANG, Jordon K.; c/o LakePharma, Inc., 530 Harbor Boulevard, Belmont, California 94002 (US).

(74) Agent: CROTTY, Justin et al.; SAUL EWING

ARNSTEIN & LEHR LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102 (US).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: HUMANIZED ANTI-EMAP II THERAPEUTIC ANTIBODIES



	SEQ ID NO 1 and 6	SEQ ID NO 2 and 6	SEQ ID NO 3 and 6	SEQ ID NO 4 and 6	SEQ ID NO 5 and 6	SEQ ID NO 10 and 11	Rat parental
EC50 (ug/mL)	0.098	0.076	0.082	0.198	0.163	0.361	3.605

FIG. 1

(57) Abstract: The present disclosure provides monoclonal antibodies that bind to endothelial monocyte activating polypeptide II and methods of treatment using the same.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*